Oncology

Latest News

Experimental Drug Dordaviprone Shows Promise Against Rare, Incurable Brain Tumor in Study
Experimental Drug Dordaviprone Shows Promise Against Rare, Incurable Brain Tumor in Study

March 4th 2024

ONC201 (dordaviprone) displayed “well tolerated and durable and clinically meaningful efficacy in Histone 3 (H3) K27M mutant-diffuse midline glioma DMG.”

Image credit: @ Giovanni Cancemi
Smoking and Certain Mutations Are Risks For Lung Cancer. But Your Immune System’s Ability to Ferret Out Early Cancer May Be Another One, Researchers Find

February 22nd 2024

Image credit: © Srdjan   stock.adobe.com
Housing Linked to Lower Cancer Mortality Among U.S. Veterans

February 8th 2024

Image credit: Casimiro  stock.adobe.com
American Cancer Society, Pfizer Join Forces on Breast, Prostate Cancer Disparity Initiative

February 5th 2024

andrey_orlov-stock.adobe.com
8 Cancer Predictions for 2024

February 1st 2024

Video Series
Video Interviews
Podcasts
Latest CME Events & Activities

Dialogues with the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: What Do Current Data for IO- and ALK-Targeted Strategies Tell Us?

March 19, 2024

Register Now!

Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse

View More

Go To PER in Chicago

May 31, 2024 - June 2, 2024

Register Now!

The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward

View More

Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target

View More

Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC

View More

Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?

View More

Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC

View More

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

22nd Annual Winter Lung Cancer Conference®

January 31, 2025 - February 2, 2025

Register Now!

Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News

© 2024 MJH Life Sciences

All rights reserved.